

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

AK112-306/HARMONI-6 MET PRIMARY ENDPOINT OF PFS SUPERIORITY IVONESCIMAB PLUS CHEMO DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS VS. TISLELIZUMAB PLUS CHEMO IN 1L SQ-NSCLC

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that its global first-in-class PD-1/VEGF bispecific antibody, ivonescimab, plus chemo, has demonstrated strong positive results in the Phase III clinical trial (AK112-306/HARMONi-6) for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC). The Independent Data Monitoring Committee (IDMC) declared the study met its primary endpoint of progression-free survival (PFS). The results of HARMONi-6 are both statistically significant and clinically meaningful. Detailed results of HARMONi-6 study will be presented at an upcoming medical conference later this year.

HARMONi-6 (CTR 20231272/NCT05840016) enrolled 532 participants, among which approximately 63% were central type of squamous cell carcinoma, which is consistent with real-world patient populations.

The results showed:

- Among intent-to-treat (ITT) populations, ivonescimab plus chemo decisively beat tislelizumab plus chemo in PFS.
- Ivonescimab group demonstrated clinically meaningful PFS benefits in both PD-L1-positive and PD-L1-negative populations.

- Ivonescimab demonstrated a favorable safety profile, with no new safety signals identified. The incidence of treatment-related serious adverse events and the incidence of bleeding events of grade 3 or higher were comparable to those of the control group.

This is ivonescimab's third Phase III clinical trial with positive results in lung cancer and ivonescimab's second Phase III clinical trial with positive results in lung cancer in head-to-head comparisons vs. PD-1 inhibitors. The positive results of this trial highlight that treatment with ivonescimab can overcome the limitations of bevacizumab in treating sq-NSCLC, ultimately enhancing the clinical benefits of immunotherapy for NSCLC. With its combine immune and anti-angiogenic mechanisms, ivonescimab offers a promising new treatment option for patients with advanced sq-NSCLC. The positive results of AK112-306/HARMONi-6 study further establish ivonescimab as a comprehensive treatment option for both first-line and later-line NSCLC, and position ivonescimab to improve upon and replace the current standard of care for the treatment of NSCLC.

ABOUT AK112-306/HARMONI-6

AK112-306/HARMONi-6 (CTR20231272/NCT05840016) is a randomized, double blind, multi center phase III trial to evaluate ivonescimab plus chemo versus tislelizumab plus chemo as first-line treatment for locally advanced or metastatic sq-NSCLC. This trial was conducted at 66 clinical sites across China, enrolled 532 participants, among which approximately 63% were central type of squamous cell carcinoma, which is consistent with real-world patient populations.

ABOUT 依達方® (IVONESCIMAB, PD-1/VEGF)

依達方® (ivonescimab, PD-1/VEGF) is a novel global first-in-class PD-1/VEGF bi-specific immuno-therapy drug independently developed by the Company. On May 24, 2024, 依達方® was granted marketing approval by NMPA for the treatment of EGFR mutated locally advanced or metastatic non-squamous NSCLC patients who have progressed after EGFR TKI treatment. Currently, one sNDA of ivonescimab is under final review stage. The Company is conducting 12 phase III trials including 3 global MRCTs and 6 trials versus PD-(L)1. The Company is also conducting multiple clinical trials of ivonescimab covering 18 indications including lung cancer, biliary tract cancer, head and neck squamous carcinoma, triple negative breast cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and executive Director

Hong Kong, April 23, 2025

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.